IntegriCell™ : Standardizing Cryopreservation For A Sustainable Cell Therapy Supply Chain

Maintaining the integrity and viability of starting materials is one of the most complex challenges in the development of cell-based therapies. Fresh leukapheresis, though widely used, can introduce significant risks due to its sensitivity to time, handling, and transportation conditions. IntegriCell™ cryopreservation services provide a robust solution to these challenges by enabling a standardized approach to preserving leukapheresis material for therapeutic use. With a focus on consistency and safety, IntegriCell™ supports long-term stability and reliability across the entire supply chain.

The process begins with the secure and timely transport of leukapheresis from collection centers to designated cryopreservation sites. There, the material undergoes an automated closed process (ACP) that cryopreserves cells ideally within 24 hours of collection—an essential window for maintaining cell quality. This method is enhanced by rigorous quality control measures to ensure that potency and viability are preserved.

By streamlining each step of the preservation journey, this approach significantly reduces risk, enhances reproducibility, and improves overall product quality. Examine how this innovation is transforming workflows in cell therapy.